Coline Furrer
12 Papers
Coline Furrer is an academic researcher. The author has contributed to research in topics: Cancer research & Tumor microenvironment. The author has an hindex of 1, co-authored 6 publications.
Chat about Author
Papers
Immune Modulations of the Tumor Microenvironment in Response to Phototherapy
Trisha I. Valerio,Coline Furrer,Negar Sadeghipour,Sophia-Joy X. Patrock,Sayre A. Tillery,Ashley R. Hoover,Kaili Liu,Wei R. Chen +7 more
TL;DR: In this article , the authors reviewed the synergistic effects of phototherapy combined with different cancer therapies on tumor elimination and remodeling of the immunosuppressive tumor microenvironment (TME), and showed that phototherapy alone has limited effects on long-term and systemic anti-tumor immune responses.
5
A novel biopolymer synergizes type I IFN and IL-1β production through STING
Ashley R. Hoover,Kaili Liu,Samuel Siu Kit Lam,Chun Fung Wong,Alexandra D. Medcalf,Xiaohui Sun,Tomas Hode,Luciano Alleruzzo,Coline Furrer,Trisha I. Valerio,Wei R. Chen +10 more
TL;DR: GC’s unique ability to activate STING and stimulate a broad type I IFN response which holds therapeutic promise in generating antitumor and antiviral immunities is demonstrated.
2
Single-cell transcriptomics reveals that tumor-infiltrating natural killer cells are activated by localized ablative immunotherapy and share anti-tumor signatures induced by immune checkpoint inhibitors
Kaili Liu,Negar Sadeghipour,Ashley R. Hoover,Trisha I. Valero,Coline Furrer,Abdul Rafeh Naqash,Meng Zhao,James F. Papin,Wei R. Chen +8 more
TL;DR: In this paper , a localized ablative immunotherapy (LAIT) by synergizing photothermal therapy (PTT) with intra-tumor delivering of the immunostimulant N-dihydrogalactochitosan (GC), was applied to treat breast cancer using a mammary tumor virus-polyoma middle tumor-antigen (MMTV-PyMT) mouse model.
N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection.
Ashley R. Hoover,Sunil More,Kaili Liu,Connor L. West,Trisha I. Valerio,Coline Furrer,Jacob P. Adams,Ningli Yu,C. Villalva,Amit Kumar,Luciano Alleruzzo,Samuel S.K. Lam,Tomas Hode,James F. Papin,Wei R. Chen +14 more
TL;DR: The efficacy of using a unique biopolymer, N-dihydrogalactochitosan (GC), as a nasal mucosal vaccine adjuvant against SARS-CoV-2 and potentially other respiratory viruses is described.
1